Comparison of Lu-177 obtained from two different commercial vendors for peptide receptor radionuclide therapy of neuroendocrine tumor patients: Preliminary results

被引：0
|
作者：
Lehmann, C. [1 ]
Prasad, V. [1 ]
Schuchardt, C. [1 ]
Mueller, D. [1 ]
Zachert, C. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zentralklin Bad Berka, Ctr PET CT, Clin Nucl Med, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [21] Outcome of Peptide Receptor Radionuclide Treatment with Lu-177 DOTATATE from Ankara University.
    Soydal, C.
    Peker, A.
    Ozkan, E.
    Kucuk, O. N.
    Kir, M. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [22] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [23] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
  • [24] Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Minczeles, Noemie S.
    de Herder, Wouter W.
    Feelders, Richard A.
    Verburg, Frederik A.
    Hofland, Johannes
    Brabander, Tessa
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 40 - 46
  • [25] Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 877 - 879
  • [26] 177Lu/90Y-SSTR Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor Cardiac Metastases
    Zhang, Jingjing
    Jakobsson, Vivianne
    Chen, Xiaoyuan
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Survival benefits and efficacy of peptide receptor radionuclide therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in pancreatic neuroendocrine tumor (pNET)
    Prasad, V.
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [28] Pancreatic Neuroendocrine Tumor (pNET): Survival Benefits and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Using Y-90/Lu-177 DOTA-TATE
    Prasad, V
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 133
  • [29] A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)
    Ross, Erin
    Ram, Lydia
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [30] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: preliminary dosimetry, efficacy and safety results from the P-PRRT trial
    Del Prete, M.
    Arsenault, F.
    Saighi, N.
    Bouchard, L. O.
    Beaulieu, A.
    Buteau, F. A.
    Beauregard, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S60 - S61
12345